Form 4: Tandem Diabetes Care Executive Reports Stock Transactions

Elizabeth Gasser, EVP, Chief Strategy Officer at Tandem Diabetes Care Inc., reported significant stock transactions including acquisitions and disposals of common stock and restricted stock units.

Summary

• Elizabeth Gasser, EVP, Chief Strategy Officer of Tandem Diabetes Care Inc., filed a Form 4 detailing stock transactions on May 15, 2026.
• The transactions include the acquisition of 1,503 shares of common stock with no cost, and the disposal of 807 shares at $12.82 each, related to tax withholding on vested RSUs.
• Further acquisitions of 1,097 shares (no cost) and disposals of 589 shares ($12.82) were reported, also linked to RSUs.
• An acquisition of 7,667 shares (no cost) and disposal of 4,114 shares ($12.82) were noted, again related to RSUs.
• An acquisition of 1,337 shares at $10.90 each was reported under the Employee Stock Purchase Plan (ESPP).
• Following these transactions, Gasser beneficially owns 25,949 shares indirectly through The Gasser Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine stock transactions by an executive related to compensation and employee programs, rather than significant strategic shifts or financial performance indicators.

Positives

• Acquisition of 1,503 shares of common stock at $0 cost, related to RSU vesting.
• Acquisition of 1,097 shares of common stock at $0 cost, related to RSU vesting.
• Acquisition of 7,667 shares of common stock at $0 cost, related to RSU vesting.
• Acquisition of 1,337 shares of common stock at $10.90 each through the ESPP, indicating participation in employee ownership programs.

Negatives

• Disposal of 807 shares of common stock at $12.82 each, to satisfy tax withholding requirements.
• Disposal of 589 shares of common stock at $12.82 each, to satisfy tax withholding requirements.
• Disposal of 4,114 shares of common stock at $12.82 each, to satisfy tax withholding requirements.

Risks

• Tax withholding requirements leading to the disposal of shares.
• Vesting schedules of Restricted Stock Units (RSUs) may lead to future share disposals.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executives and directors regarding their company stock transactions, providing transparency into insider activity. The reported transactions for Tandem Diabetes Care Inc. are typical for an executive managing equity compensation and participating in employee stock purchase plans.

Stakeholder Impact

• Shareholders: Increased transparency into insider stock holdings and transactions.
• Employees: Participation in ESPP and RSU programs indicates employee incentive and ownership opportunities.
• Management: Demonstrates executive engagement with company stock through compensation plans.

Next Steps

• Vesting of remaining shares for RSUs awarded on May 25, 2023, in eight equal quarterly installments after May 15, 2024.
• Vesting of remaining shares for RSUs awarded on May 23, 2024, in eight equal quarterly installments after May 15, 2025.
• Vesting of remaining shares for RSUs awarded on May 30, 2025, in eight equal quarterly installments after May 15, 2026.

Key Dates

Keywords

Form 4, Tandem Diabetes Care, TNDM, Elizabeth Gasser, Stock Transaction, Beneficial Ownership, Restricted Stock Units, RSU, Employee Stock Purchase Plan, ESPP, Insider Trading, SEC Filing